Hosted by Unknown Host · 🇺🇸 US · EN-US · 184 episodes
Established thought leaders with verified media credentials.
Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.
Unknown Host hosts Retina Synthesis, a education show with 184 episodes published.
In this episode, we discuss the promising results of intravitreal gene therapy for neovascular AMD with 4D-150 with Dr. Arshad Khanani of Sierra Eye Associates and Clinical Professor of Ophthalmology at the University of
In this episode, we discuss the latest developments in the use of artificial intelligence in home OCT for management of neovascular AMD with Professor Anat Loewenstein of Tel Aviv Medical Center and President, Israeli Op
We discuss long term results of faricimab treatment of DME, with the first author of the Ophthalmology article on the results of Rhone-X trial, Dr. Veeral Sheth, Director of Clinical Research at University Retina in Chic
In our latest episode we discuss the results of a novel approach to the treatment of geographic atrophy using Xelafaslatide a Fas inhibitor with Dr. David Zacks, Professor of Ophthalmology at the Kellogg Eye Center at th
In our latest episode, we discuss the use of inhibitors of IL-6 in the treatment of retinal disease with Dr. Steven M. Yeh, Stanley M. Truhlsen, Jr. , Chair of Ophthalmology a the University of Nebraska.
In this episode, we discuss the use of aflibercept 8mg for the management of retinal vein occlusion and the results of the QUASAR study with Dr. Sunir Garg, Co Director of Retina Research at the Wills Eye Hospital and Pr
In this episode we discuss the results of a phase 2 trial using subcutaneous elamipretide for the treatment of geographic atrophy with Dr. Mark Barakat.
In this episode, we discuss the 3 year results of the Phase 2 trial of the Adverum intravitreal gene therapy with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Professor Ophthalmology, Keck School of
In this episode we discuss the impressive Phase 4 results of the Belvedere Trial for treatment of neovascular AMD with Dr. Michael Klufas of Wills Eye Hospital.
In our latest episode with the discuss the promising results of a Phase I clinical trial looking at kamuvudine 8 an inflammasome inhibitor in the treatment of geographic atrophy with Dr. Jayakrishna Ambati, Guerry Profes
In this episode, we discuss real world treatment of proliferative diabetic retinopathy using data from the Vestrum data base; with Dr. Adrienne Scott, Fred M. Leader Family Retina Professor of the Wilmer Eye Institute an
In this episode, we discuss the pathbreaking use of an encapsulated cell therapy that produces CNTF for the successful treatment of MacTel with Roger Goldberg, MD, from Walnut Creek, CA.
In our latest update, we discuss strategies for developing a teleretinology network with Dr. Glenn Yiu, Professor of Ophthalmology, University of California, Davis.
In our latest update we discuss the prevention and treatment of endophthalmitis with one of the world's leading authorities, Dr. Harry Flynn , holder of the J. Donald M. Gass Distinguished Chair In Ophthalmology at the B
We discuss early studies of ophthalmic artery angioplasty in cases of advanced geographic atrophy with Dr. Philip Rosenfeld of the Bascom Palmer Eye Institute.
In our latest episode, we discuss the results of the PRIMA retinal implant in treating eyes with center involved geographic atrophy as presented in a recent New England Journal of Medicine article. 85% of eyes had meanin
In this episode, In our latest episode, we discuss the results of a randomized trial comparing the Iluvien sustained release steroid implant to aflibercept in the treatment of diabetic macular edema with Dr. Michael Sing
We discuss the diagnosis and management of central serous chorioretinopathy with photodynamic therapy with Dr. Andrew Lotery, Professor of Ophthalmology, University of Southhampton, United Kingdom.
In this episode, we discuss the use of low dose cryogenic application for anesthesia prior to intravitreal injection with Dr. Michael Singer, Adjunct Professor University of Texas Health Science Center, San Antonio.
In our latest update, we discuss current treatment of retinopathy of prematurity as well as new developments in disease prevention with Dr. Darius Moshfeghi, Professor of Ophthalmology, Stanford University, Director, Ret
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch Retina Synthesis, visit https://retinasynthesis.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent education coverage.
Retina Synthesis is hosted by Unknown Host. The show is categorised under education and has published 184 episodes.
Retina Synthesis has published 184 episodes.
Retina Synthesis regularly covers education. It sits in the education category.
Retina Synthesis is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Retina Synthesis hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Retina Synthesis average 19 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Retina Synthesis's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 4 days ago.
